Pediatric renal transplantation under tacrolimus-based immunosuppression

Transplantation

Volumn 67, Issue 2, 1999, Pages 299-303

  Shapiro, Ron ^a   Scantlebury, Velma P ^a   Jordan, Mark L ^b   Vivas, Carlos ^b   Ellis, Demetrius ^c   Lombardozzi Lane, Susan ^c   Gilboa, Nisan ^c   Gritsch, H Albin ^b   Irish, William ^a   McCauley, Jerry ^a   Fung, John J ^a   Hakala, Thomas R ^b   Simmons, Richard L ^c   Starzl, Thomas E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PREDNISONE; TACROLIMUS;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CADAVER KIDNEY; CHILD; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; REOPERATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TACROLIMUS; TISSUE DONORS;

EID: 0033608112     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199901270-00020     Document Type: Article

References (32)

1. Starzl TE, Fung J, Jordan M, et al. Kidney transplantation under FK 506. JAMA 1990; 264: 63.
2. Shapiro R, Jordan M, Fung J, et al. Kidney transplantation under FK 506 immunosuppression. Transplant Proc 1991; 23: 920.
3. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995; 59: 485.
4. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation: a report of the U.S. Multicenter FK506 Kidney Transplant Group Transplantation. Transplantation 1996; 61 (11): 1576.
5. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62 (7): 900.
6. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977.
7. Miller J, Pirsch JD, Deierhoi R. FK506 in kidney transplantation: results of the U.S.A. Randomized Comparative Phase III Study. Transplant Proc 1997; 29: 304.
8. Ochiai T, Ishibashi M, Fukao K, et al. Japanese multicenter studies of FK506 in renal transplantation. Transplant Proc 1995; 22 (1): 50.
9. Mayer AD, Dmitrewski J, Squifflet, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64 (3): 436.
10. Shapiro R. Tacrolimus (FK-506) in kidney transplantation. Transplant Proc 1997; 29: 45.
11. Jensen CWB, Jordan ML, Schneck FX, et al. Pediatric renal transplantation under FK 506 immunosuppression. Transplant Proc 1991; 23: 3075.
12. Schneck FX, Jordan M, Jensen CWB, et al. Pediatric renal transplantation under FK-506 immunosuppression. J Urol 1992; 147 (6): 1585.
13. Scantlebury V, Shapiro R, Tzakis A, et al. Pediatric kidney transplantation at the University of Pittsburgh. Transplant Proc 1994; 26 (1): 46.
14. Ellis D, Shapiro R, Jordan ML, et al. Comparison of FK506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol 1994; 8 (2): 193.
15. Shapiro R, Tzakis A, Scantlebury V, et al. Improving results of pediatric kidney transplantation. J Am Coll Surg 1994; 179 (4): 424.
16. Shapiro R, Scantlebury VP, Jordan ML, et al. FK506 in pediatric kidney transplantation: primary and rescue experience. Pediatr Nephrol 1995; 9: S43.
17. Shapiro R, Scantlebury VP, Jordan ML, et al. Tacrolimus in pediatric renal transplantation. Transplantation 1996; 62 (12): 1752.
18. Birk PE, Cook ME, Schmidt WJ, Chavers BM. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report. Transplant Proc 1996; 28 (2): 993.
19. McKee M, Segev D, Wise B, et al. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients. J Pediatr Surg 1997; 32 (5): 688.
20. Offner G, Latta K, Bokenkamp A, Hoyer PF. Tacrolimus for rescue of renal transplantation in children: the II International Congress on Pediatric Transplantation, August 22-24 [Abstr. S18]. Pediatr Nephrol 1996; 10 (4): C62.
21. Carroll PB, Rilo H, Reyes J, et al. FK-506 associated diabetes mellitus in the pediatric transplant population is a rare complication. Transplant Proc 1991; 23: 3171.
22. Snydman DR (ed). Proceedings of a symposium on high-risk transplantation. Transplant Proc 1994; 26 (5) (Suppl 1): 45.
23. Delone P, Corkill J, Jordan M, et al. Successful treatment of Epstein-Barr virus infection with ganciclovir and cytomegalovirus hyperimmune globulin following kidney transplantation. Transplant Proc 1995; 27 (5) (Suppl 1): 58.
24. Green M, Reyes J, Todo R, Rowe DT. Use of quantitative competitive PCR (QC-PCR) to guide preemptive therapy (PT) against EBV associated post-transplant lymphoproliferative disorders (PTLD) after intestinal transplantation (ITx) in children. Transplant Proc 1996; 28: 2759.
25. Filler G, Amendt P, Von Bredow MA, Ehrich JH. Transient diabetes mellitus and peripheral insulin resistance following tacrolimus intoxication in a child after renal transplantation. Nephrol Dialysis Transplant 1997; 12 (2): 334.
26. Shapiro R, Scantlebury VP, Jordan ML, et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc 1997; 29 (6): 2737.
27. McCauley J, Takaya S, Fung J, et al. The question of FK506 nephrotoxicity after liver transplantation. Transplant Proc 1991; 23: 1444.
28. Starzl TE, Abu-Elmagd K, Tzakis A, Fung JJ, Porter KA, Todo S. Selected topics on FK506, with special references to rescue of extraheptic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc 1991; 23: 914.
29. Starzl TE. FK506 versus cyclosporine. Transplant Proc 1993; 25: 511.
30. Demetris AJ, Banner B, Fung JJ, Shapiro R, Jordan M, Starzl TE. Histopathology of human renal allograft function under FK506: a comparison with cyclosporine. Transplant Proc 1991; 23: 944.
31. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993; 17: 60.
32. Shapiro R, Fung JJ, Jain AB, Parks P, Todo S, Starzl TE. The side effects of FK506 in humans. Transplant Proc 1990; 22 (1): 35.